What Is The Current and Historic Market Size Analysis Of The Next-Generation Antibody Therapeutics Market?
The next-generation antibody therapeutics market has seen considerable growth due to a variety of factors.
•The market size for next-generation antibody therapeutics has seen significant expansion in recent years. The forecasts anticipate an expansion from $6.82 billion in 2024 to $7.63 billion in 2025, a compound annual growth rate (CAGR) of 11.8%.
Factors such as the success of monoclonal antibodies, increased incidence of chronic diseases, approval of antibody-drug composites, and advancements in immunotherapy, gene therapy, and antibodies have been instrumental in driving the growth during the historic period.
What Are The Predictions for The Next-Generation Antibody Therapeutics Market Size In The Coming Years?
The next-generation antibody therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for next-generation antibody therapeutics is projected to experience significant growth. By 2029, it is estimated to expand to $11.52 billion, exhibiting a compound annual growth rate (CAGR) of 10.9%.
Factors contributing to this growth during the forecast period include development of biosimilars, bispecific antibodies, and nanobodies, patient-oriented strategies, immunomodulatory antibodies, and broadening uses in autoimmune diseases, as well as continuous manufacturing. The period's key trends will involve progress in antibody engineering, the use of digital technologies in antibody design, collaborations within the industry, advancements in systems for drug delivery, and the application of real-world evidence in the development of antibodies.
Which Key Drivers Are Propelling The Next-Generation Antibody Therapeutics Market's Growth?
Growth in the next-generation antibody therapeutics market is expected to be fueled by a rise in chronic diseases. Such diseases, which are long-term conditions requiring ongoing medical attention and often limit daily activities, find therapeutic relief through next-generation antibody therapeutics. These offer more targeted treatments beneficial to patients suffering from these conditions. For instance, data from the National Center for Biotechnology Information (NCBI), a department within the US-based National Library of Medicine, predicted in January 2023 that individuals aged 50 years and older with at least one chronic disease will increase by 99.5%, representing about 142.66 million people, by 2050. Consequently, the growing incidence of chronic diseases is a significant factor propelling the expansion of the next-generation antibody therapeutics market.
What Are The Key Segments Within The Global Next-Generation Antibody Therapeutics Market?
The next-generation antibody therapeutics market covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies
Pre-Book The Next-Generation Antibody Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Next-Generation Antibody Therapeutics Market?
The growth of technological innovations is a prominent trend emerging in the market for next-generation antibody therapeutics. Many major corporations working in this market, are concentrating on technological advancements such as Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. They aim to develop and augment protein identification and characterization for more precise and potent treatment methods. These innovations strive to boost therapeutic profiles, lessen costs, and offer detailed solutions to complicated diseases. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a system that structures protein molecules for better analysis and quantification, enhancing accuracy and sensitivity in protein detection, beneficial for research and diagnostics. For instance, in January 2024, Infinity Bio, Inc., a biotechnology firm based in the US, introduced a next-generation antibody profiling platform, utilizing MIPSA technology for extensive, cost-effective analysis of immune responses, with the aim of improving disease comprehension and personalizing treatment strategies.
Who Are the Key Players in the Next-Generation Antibody Therapeutics Market?
Major companies operating in the next-generation antibody therapeutics market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Celgene Corporation
• Lonza Group AG
• Catalent Inc.
• Genentech Inc.
• Kyowa Hakko Kirin Co. Ltd.
• Samsung Biologics
• WuXi Biologics
• Seagen Inc.
• Seattle Genetics Inc.
• Xencor Inc.
• ImmunoGen Inc.
What are the Regional Insights into the Next-Generation Antibody Therapeutics Market?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
